Occurrence and prevalence of NUB. The year-dependent distribution of female newborns, NUB+ cases and prevalence of NUB are shown in Table 1. Among 807 female babies born at our hospital between 2013 and 2017, NUB occurred in 25 cases with a prevalence of 3.1% (Table 1, A). Among the 1083 female newborn babies born between 1996 and 2000, 105 cases had NUB with a prevalence of 9.7% (Table 1, B). Twenty-five NUB cases born between 2013 and 2017 showed overt bleeding 4.5±1.8 days (median 4 days, range 1-8 days) after birth and it lasted for 1.4±0.8 days (median 1 day, range 1-4 days). In 105 cases born between 1996 and 2000, NUB was seen to occur 4.4±1.2 days (median 4 days, range 0-7 days) after birth and continued for 1.9±1.1 days (median 2 days, range 1-6 days). Five of 25 cases (20%) showed NUB in their diapers after the 7th day during the period 2013-2017 and 4 of 105 cases (3.8%) showed NUB on day 7 during the period 1996-2000. If any NUB continued until discharge from our hospital, the duration is the number of days until the day of discharge. We could not collect any information on the possible occurrence of NUB after discharge from the hospital. Therefore, cases with occurrence of any NUB after discharge was not included in this study. The occurrence of any visible neonatal bleeding until the time of discharge was observed by attending doctors or nurses and this information is routinely noted in medical records of our hospital. There was no significant difference in the presence or absence of NUB between babies, delivered by Cesarean section, staying in the hospital for 7 days or more and babies delivered vaginally staying in the hospital within 7 days.
The average gestational age at birth of NUB+ cases was 39.2±1.3 weeks during the period of 2013-2017 and 39.6±1.1 weeks in 1996-2000 without showing any significant difference in gestational age between these two time periods. Maternal age of NUB+ cases was similar between mothers in 1996-2000 and in 2013-2017 (30.4±4.4 vs. 31.2±5.1 years, P=0.58). On the other hand, gestational age at birth of all cases in 1996-2000 was significantly longer than that of cases in 2013-2017 (37.9±3.1 vs. 37.5±2.6 weeks, P<0.0001). Almost all NUB+ cases were term babies except for one case who was born at the gestational age of 36 weeks. The detail clinical characteristics of female babies born with and without NUB and their mothers during the period of 2013-2017 are shown in Table 2 and Table 3. Analysis of continuous variables between groups indicated that gestational age was longer, body height was taller, body weight was heavier, head/chest circumference was wider in NUB+ cases than in NUB- cases (Table 2). The occurrence of NUB in newborn babies was significantly higher in primipara than in multipara mothers without showing remarkable pregnancy related complications. The majority of NUB+ cases were born by vaginal delivery (Table 3).
Risk factors associated with NUB (2013-2017). To identify the risk factors for NUB, we selected several confounding factors such as gestational age at birth, maternal age, abnormalities at delivery, medical history of mother, pregnancy complications, and disease of the child. After a backward selection of variables with a p value of <0.2 as analyzed by univariate analysis, we conducted multivariate logistic regression analysis. Risk of NUB significantly increased in babies born at 39 weeks (OR, 3.87, 95% CI 1.18-12.7, P=0.026) or ≥40 weeks of gestational age (OR, 10.2, 95% CI 3.58-28.9, P<0.001) compared with the babies born at ≤38 weeks (Table 4). Younger age of the mother appeared to be significantly associated with the occurrence of NUB (OR, 0.92, 95% CI 0.85-1.00, P=0.048) This finding conversely indicates that as the maternal age increased by 1 year, the frequency of NUB significantly decreased by 0.92 times. The presence of maternal intestinal disease, atopic dermatitis, non-reassuring fetal status (NRFS), and neonatal hydronephrosis were also the significant risk factors for NUB (Table 4).
Risk factors associated with NUB (1996-2000). In order to identify the risk factors associated with NUB of female babies born in our hospital between 1996 and 2000, we first performed univariate analysis with different confounding variables such as gestational age, maternal history, and neonatal biophysical conditions. A multivariate logistic regression analysis was performed on these and other 6 factors which were found to be significantly associated with NUB in the 2013-2017 analysis. We found that similar to the period of 2013-2017, NUB increased significantly in babies born at 39 weeks (OR 3.04, 95% CI 1.43-6.45, P=0.004) and ≥40 weeks (OR 4.54, 95% CI 2.20-9.39, P<0.0001) of gestation compared with ≤38 weeks of gestation (Table 5). Although maternal age did not show any risk association with NUB, increasing birth weight of newborns was modestly associated with the occurrence of NUB (OR 1.07, 95% CI 1.01-1.13, P=0.025) during 1996-2000. Other confounding factors and their association with NUB are shown in Table 5.
Symptoms related to endometriosis based on questionnaire survey. In an attempt to find an association between the occurrence of NUB and symptoms related to endometriosis, we conducted a web-based questionnaire survey among young women who were born with and without NUB during the period of 1996-2000. Among 1083 female babies (11 cases with no available data were excluded) born at our University Hospital, 105 cases showed occurrence of NUB. Among cases without NUB, 205 cases born at ≤36 weeks of gestation were excluded because the gestational ages of NUB+ cases at birth were all 37 weeks or later. We contacted 105 NUB+ cases and 771 NUB- cases by individual telephone call to the phone number listed in the medical records and we could approach to 55 cases with NUB and 149 cases without NUB. We properly explained the research purpose of our web-based questionnaire survey and they gave us verbal informed consent. Finally, responses to the questionnaires survey were obtained from 31 NUB+ women and 52 NUB- women. A flow chart of cases who participated in the online questionnaire survey is shown in the Figure. 1. All participants declined to take a physical examination/ultrasound/MRI or laparoscopy to confirm the diagnosis of their symptoms, if any. The demographic profiles of each group of women who were born with and without NUB and responded to questionnaires are showed in Table 6. Women with a history of NUB were significantly younger than those without NUB (median, 21 vs. 23 yrs. P=0.039). Gestational age at delivery of NUB+ cases was significantly longer than that of NUB- cases (median, 40 vs. 39 weeks, P=0.036).
In the questionnaire survey, participants responded to 10 different questions about the symptoms related to menstrual pain and medication. We compared the responses to the questionnaires between 31 NUB+ cases and 52 NUB- cases. There was no significant difference in the complain of cyclic pain and/or severity of cyclic/acyclic pain (VAS score 7-10), number of painful days, disturbance of daily life activity during cyclic/acyclic pain, number of women missing school or work, taking hormonal or non-hormonal medication, duration and effect of medication (Table 7). While acyclic pain was significantly higher in the group without NUB, this difference was lost in the multiple logistic regression analysis. Analgesics and hormonal drugs were useful in relieving pain in more than 90% of women who used them, but there was no difference between groups. Pregnancy was found in 3 women in the NUB- group only and therefore, could not be compared with NUB+ group. A graphic representation showing responses to eight different questionnaires in women with and without NUB is shown in Figure 2. Univariate and multivariate logistic regression analysis were performed to evaluate the associations between the questionnaire responses and each characteristic of participants (Table 8A-F).
Association between response to questionnaires and clinical profiles of participants. Six different outcomes (A1, A2, A4, A5, A6, A8 of Table 7) as binary dependent variable and 14 independent variables including NUB were considered for univariate and multivariate logistic regression analysis. Outcome A1: “do you feel pain during period (cyclic)?” NUB was not associated with the presence of cyclic pain but young women with their higher maternal age significantly more frequently feel cyclic pain (OR 1.37, 95%CI 1.02-1.84, p=0.039). There was a tendency that women with low BMI (slender women) have cyclic pain (OR 0.74, 95%CI 0.54-1.01, p=0.053) (Table 8A). Outcome A2: “do you feel pain beyond period (acyclic)?” As for acyclic pain, young women with a family history of acyclic pain significantly more frequently (6.6 times) complain of acyclic pain (OR 6.59, 95%CI 1.07-40.4, p=0.042) but NUB was not associated with it (Table 8B). Outcome A4: “degree of your cyclic pain (VAS score)?” Three independent variables were associated with this outcome. The cyclic pain with a VAS score of 7-10 (severe pain) was significantly associated with the longer gestational age at delivery than in women with mild to moderate levels of cyclic pain (VAS score 0-6) (OR 2.08, 95%CI 1.12-3.86, p=0.020). Similarly, women complaining of the severe pain had significant (about 7 times) menstrual lag of ≥7 days (OR 6.96, 95%CI 1.46, 33.2, p=0.015) but revealed no association with NUB. Moreover, young women with early onset of menarche tend to more frequently complain of severe cyclic pain (VAS score 7-10) than in women with mild to moderate degree of cyclic pain (VAS 0-6) (OR 0.66, 95%CI 0.43-1.02, p=0.063) (Table 8C). Outcome A5: “degree of your acyclic pain (VAS score)?” The acyclic pain with a VAS score of 7-10 was not associated with the presence of NUB. Comparing to taller women (median, 160cm) young women with shorter body height (median, 156cm) had a tendency to more frequently complain of severe acyclic pain than in women with mild to moderate degree of acyclic pain (OR 0.83, 95%CI 0.67-1.02, p=0.074) (Table 8D). Outcome A6: “does your cyclic/acyclic pain disturb daily life activity?” Age was the only independent variable associated with this outcome. Younger women (median, 22yrs.) complained that suffering from severe cyclic and acyclic pain significantly and more frequently disturb their daily life activity (OR 2.67, 95%CI 1.01- 7.06, p=0.047) (Table 8E). Outcome A8: “do you take any pain killer or hormonal therapy for your cyclic pain?” Among 14 independent variables, two variables were associated with this outcome such as age at menarche and normal menstrual cycle. Young women with early onset menarche (median, 12 yrs.) significantly more frequently need to take pain-killer or hormonal therapy to relieve their cyclic pain (OR 0.61, 95%CI 0.38-0.97, p=0.038). Women who have normal menstrual cycle significantly more frequently (>6 times) need to take pain killer or hormonal therapy to relieve their cyclic pain (OR 6.31, 95%CI 1.26-31.6, p=0.025) (Table 8F). NUB had no association with this outcome.